Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Kiran V. Relekar"'
Autor:
William E. Carson, Cheryl Kefauver, Lai Wei, Kari Kendra, Cynthia Taylor, Valerie P. Grignol, Helen X. Chen, Amanda Kibler, Kiran V. Relekar, Thomas Olencki, Michael Walker
Publikováno v:
Journal of Immunotherapy. 34:509-515
Bevacizumab is a humanized recombinant monoclonal antibody that neutralizes vascular endothelial growth factor, an agent with proangiogenic effects in melanoma. Interferon alpha (IFN-α) has antiangiogenic properties through its ability to downregula
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1f167d8e153ad7366a91b4e25d27d5cb
https://doi.org/10.1097/cji.0b013e31821dcefd
https://doi.org/10.1097/cji.0b013e31821dcefd
Autor:
Thomas Olencki, Kristan D. Guenterberg, Valerie P. Grignol, Kiran V. Relekar, Kari Kendra, Kimberly A. Varker, William E. Carson, Helen X. Chen
Ocular melanomas represent 5% of all melanomas; of these, 85% are uveal (ie, involving the iris, ciliary body, or choroid), making it the most common primary intraocular tumor.1,2 Uveal melanoma is more common in males and whites. However, unlike cut
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::64f75515864f751434dc30d01dda8691
https://europepmc.org/articles/PMC4294796/
https://europepmc.org/articles/PMC4294796/
